Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review

Wendy J. Boschloo, Berend J. van Welzen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Downloads (Pure)

Abstract

The human immunodeficiency virus type 2 (HIV-2) is a particular subtype of HIV, which is endemic in West Africa and is characterized by a more indolent course than HIV-1. As people living with HIV-2 (PWH-2) are at risk for the development of acquired immunodeficiency syndrome and can transmit the virus, antiretroviral therapy is usually indicated. However, the optimal treatment of HIV-2 is unknown and historically the protease inhibitors (PIs) were a regular part of therapy. Nowadays, the use of integrase strand transfer inhibitors (INSTIs) in HIV-2 is increasing but the evidence supporting this approach is limited. In this narrative review, we outline the clinical data on the use of INSTI-containing antiretroviral therapy in HIV-2. We found that in the setting of treatment-naïve PWH-2, the use of INSTIs is successful, but also noted large heterogeneity in reported outcomes and that most cohorts are small with limited follow-up time. There is a lack of studies comparing the efficacy of INSTIs to other first-line options. For treatment-experienced PWH-2, the efficacy of INSTI is highly variable.

Original languageEnglish
Pages (from-to)1161-1175
Number of pages15
JournalInfectious Diseases and Therapy
Volume13
Issue number6
DOIs
Publication statusPublished - Jun 2024

Keywords

  • Antiretroviral therapy
  • Efficacy
  • HIV-2
  • Integrase strand transfer inhibitors

Fingerprint

Dive into the research topics of 'Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review'. Together they form a unique fingerprint.

Cite this